 James Moy
Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 18 | 2021 | 182 | 2.550 |
Why?
| | Antibodies, Viral | 4 | 2022 | 79 | 1.220 |
Why?
| | Immunoglobulins, Intravenous | 4 | 2018 | 25 | 1.170 |
Why?
| | Immunoglobulin G | 5 | 2021 | 134 | 1.100 |
Why?
| | Immunologic Deficiency Syndromes | 3 | 2017 | 12 | 0.960 |
Why?
| | Agammaglobulinemia | 2 | 2018 | 4 | 0.920 |
Why?
| | Antibody Formation | 1 | 2021 | 33 | 0.920 |
Why?
| | Common Variable Immunodeficiency | 2 | 2018 | 7 | 0.910 |
Why?
| | Bacterial Infections | 3 | 2018 | 71 | 0.870 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2018 | 1 | 0.730 |
Why?
| | Immunoglobulins | 1 | 2017 | 35 | 0.690 |
Why?
| | Immunologic Factors | 1 | 2017 | 53 | 0.670 |
Why?
| | Immunotherapy | 1 | 2017 | 74 | 0.660 |
Why?
| | Child, Preschool | 12 | 2019 | 786 | 0.650 |
Why?
| | Adrenal Cortex Hormones | 5 | 2019 | 100 | 0.540 |
Why?
| | Child | 12 | 2021 | 1572 | 0.540 |
Why?
| | Glucocorticoids | 4 | 2019 | 77 | 0.520 |
Why?
| | Respiratory Sounds | 2 | 2019 | 11 | 0.460 |
Why?
| | Bronchodilator Agents | 3 | 2019 | 14 | 0.440 |
Why?
| | Alendronate | 2 | 2019 | 8 | 0.400 |
Why?
| | Ibuprofen | 2 | 2021 | 12 | 0.390 |
Why?
| | Adolescent | 9 | 2019 | 2667 | 0.380 |
Why?
| | Humans | 32 | 2022 | 31481 | 0.380 |
Why?
| | Female | 22 | 2021 | 18253 | 0.370 |
Why?
| | Male | 21 | 2021 | 17583 | 0.370 |
Why?
| | Adult | 13 | 2021 | 9779 | 0.360 |
Why?
| | Double-Blind Method | 9 | 2021 | 559 | 0.340 |
Why?
| | Anti-Asthmatic Agents | 4 | 2018 | 35 | 0.330 |
Why?
| | Administration, Inhalation | 7 | 2019 | 37 | 0.320 |
Why?
| | Young Adult | 6 | 2019 | 2277 | 0.320 |
Why?
| | Middle Aged | 10 | 2021 | 11209 | 0.300 |
Why?
| | Cockroaches | 1 | 2003 | 1 | 0.270 |
Why?
| | Respiratory Hypersensitivity | 1 | 2003 | 5 | 0.270 |
Why?
| | Eosinophilia | 2 | 2017 | 49 | 0.270 |
Why?
| | Allergens | 1 | 2003 | 20 | 0.270 |
Why?
| | Acetaminophen | 3 | 2021 | 20 | 0.260 |
Why?
| | Sputum | 2 | 2019 | 23 | 0.240 |
Why?
| | Pandemics | 2 | 2021 | 203 | 0.220 |
Why?
| | Lung | 2 | 2019 | 171 | 0.210 |
Why?
| | Infant | 6 | 2018 | 642 | 0.210 |
Why?
| | Immunity, Innate | 1 | 2021 | 97 | 0.210 |
Why?
| | Prospective Studies | 4 | 2019 | 1934 | 0.210 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 3 | 0.200 |
Why?
| | Education, Medical, Continuing | 1 | 2020 | 47 | 0.200 |
Why?
| | Cohort Studies | 3 | 2021 | 2014 | 0.200 |
Why?
| | Hypersensitivity | 1 | 2020 | 54 | 0.200 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2019 | 8 | 0.200 |
Why?
| | Vitamin A Deficiency | 1 | 2018 | 1 | 0.190 |
Why?
| | Vitamin A | 1 | 2018 | 8 | 0.190 |
Why?
| | Contrast Sensitivity | 1 | 2018 | 8 | 0.190 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 375 | 0.190 |
Why?
| | Eosinophils | 1 | 2019 | 47 | 0.190 |
Why?
| | Zinc | 1 | 2018 | 40 | 0.190 |
Why?
| | Arginine | 1 | 2018 | 17 | 0.180 |
Why?
| | Glutathione | 1 | 2018 | 31 | 0.180 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 34 | 0.180 |
Why?
| | Coronavirus Infections | 1 | 2020 | 97 | 0.180 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 102 | 0.170 |
Why?
| | Leukotriene Antagonists | 1 | 2016 | 1 | 0.170 |
Why?
| | Inhalation Exposure | 2 | 2008 | 6 | 0.160 |
Why?
| | Azithromycin | 1 | 2015 | 3 | 0.160 |
Why?
| | Respiratory Tract Infections | 1 | 2015 | 25 | 0.150 |
Why?
| | Treatment Outcome | 4 | 2018 | 3910 | 0.150 |
Why?
| | Secondary Prevention | 1 | 2015 | 67 | 0.150 |
Why?
| | Research Design | 3 | 2021 | 238 | 0.140 |
Why?
| | Pregnenediones | 1 | 2014 | 3 | 0.140 |
Why?
| | Cholecalciferol | 1 | 2014 | 3 | 0.140 |
Why?
| | Vitamins | 1 | 2014 | 11 | 0.140 |
Why?
| | Vitamin D Deficiency | 1 | 2014 | 11 | 0.140 |
Why?
| | Recurrence | 3 | 2016 | 389 | 0.130 |
Why?
| | Cotinine | 2 | 2011 | 6 | 0.120 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 412 | 0.120 |
Why?
| | African Americans | 1 | 2019 | 818 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2019 | 512 | 0.120 |
Why?
| | Quality of Life | 1 | 2017 | 663 | 0.120 |
Why?
| | Dermatitis, Allergic Contact | 1 | 2011 | 7 | 0.110 |
Why?
| | Pruritus | 1 | 2011 | 15 | 0.110 |
Why?
| | Silicones | 1 | 2011 | 14 | 0.110 |
Why?
| | Peritoneal Dialysis | 1 | 2011 | 27 | 0.110 |
Why?
| | Catheters, Indwelling | 1 | 2011 | 30 | 0.110 |
Why?
| | Severity of Illness Index | 3 | 2021 | 1240 | 0.110 |
Why?
| | Mexican Americans | 1 | 2011 | 28 | 0.110 |
Why?
| | Follow-Up Studies | 3 | 2018 | 2028 | 0.100 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 580 | 0.100 |
Why?
| | Smoking | 1 | 2011 | 202 | 0.100 |
Why?
| | Cross-Over Studies | 2 | 2019 | 82 | 0.100 |
Why?
| | Prevalence | 2 | 2018 | 544 | 0.100 |
Why?
| | Tobacco Smoke Pollution | 1 | 2008 | 8 | 0.090 |
Why?
| | Saliva | 1 | 2008 | 62 | 0.090 |
Why?
| | Leukocyte Count | 2 | 2019 | 96 | 0.090 |
Why?
| | Aged | 3 | 2018 | 10295 | 0.090 |
Why?
| | Case-Control Studies | 2 | 2021 | 687 | 0.090 |
Why?
| | Albuterol | 2 | 2018 | 17 | 0.090 |
Why?
| | Models, Biological | 1 | 2008 | 428 | 0.080 |
Why?
| | Cross-Sectional Studies | 3 | 2018 | 986 | 0.080 |
Why?
| | Quinolines | 1 | 2005 | 18 | 0.080 |
Why?
| | Acetates | 1 | 2005 | 26 | 0.080 |
Why?
| | Incidence | 2 | 2018 | 829 | 0.070 |
Why?
| | Pyroglyphidae | 1 | 2003 | 1 | 0.070 |
Why?
| | Air Pollution, Indoor | 1 | 2003 | 2 | 0.070 |
Why?
| | Skin Tests | 1 | 2003 | 16 | 0.070 |
Why?
| | Urban Health | 1 | 2003 | 29 | 0.070 |
Why?
| | Cats | 1 | 2003 | 79 | 0.070 |
Why?
| | Child Welfare | 1 | 2003 | 21 | 0.070 |
Why?
| | Statistics as Topic | 1 | 2003 | 124 | 0.070 |
Why?
| | Dogs | 1 | 2003 | 283 | 0.060 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2002 | 1 | 0.060 |
Why?
| | Chemokines | 1 | 2002 | 31 | 0.060 |
Why?
| | Serologic Tests | 1 | 2022 | 15 | 0.060 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2021 | 30 | 0.060 |
Why?
| | NF-kappa B | 1 | 2002 | 112 | 0.060 |
Why?
| | Advisory Committees | 1 | 2021 | 48 | 0.060 |
Why?
| | Clinical Protocols | 1 | 2021 | 75 | 0.060 |
Why?
| | Immunization, Passive | 1 | 2021 | 20 | 0.060 |
Why?
| | Seroepidemiologic Studies | 1 | 2021 | 22 | 0.060 |
Why?
| | Receptors, Fc | 1 | 2021 | 10 | 0.060 |
Why?
| | Complement Activation | 1 | 2021 | 14 | 0.060 |
Why?
| | Immunoglobulin M | 1 | 2021 | 21 | 0.060 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2021 | 10 | 0.060 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 17 | 0.060 |
Why?
| | Antibody Specificity | 1 | 2021 | 59 | 0.060 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2021 | 24 | 0.060 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2002 | 136 | 0.060 |
Why?
| | Antibodies, Neutralizing | 1 | 2021 | 26 | 0.060 |
Why?
| | Phagocytosis | 1 | 2021 | 52 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2002 | 230 | 0.050 |
Why?
| | Education, Distance | 1 | 2020 | 18 | 0.050 |
Why?
| | Administration, Oral | 2 | 2014 | 164 | 0.050 |
Why?
| | United States | 2 | 2018 | 2539 | 0.050 |
Why?
| | Drug Combinations | 1 | 2019 | 88 | 0.050 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2019 | 45 | 0.050 |
Why?
| | Inflammation | 1 | 2021 | 360 | 0.050 |
Why?
| | Peak Expiratory Flow Rate | 1 | 2018 | 2 | 0.050 |
Why?
| | Ornithine | 1 | 2018 | 3 | 0.050 |
Why?
| | Growth | 1 | 2018 | 6 | 0.050 |
Why?
| | Medication Adherence | 1 | 2019 | 93 | 0.050 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2018 | 18 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2021 | 886 | 0.040 |
Why?
| | Forced Expiratory Volume | 1 | 2017 | 13 | 0.040 |
Why?
| | Immunoglobulin E | 1 | 2017 | 17 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2021 | 891 | 0.040 |
Why?
| | Fever | 1 | 2016 | 38 | 0.040 |
Why?
| | Chicago | 2 | 2011 | 955 | 0.040 |
Why?
| | Neutrophils | 1 | 2017 | 133 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 230 | 0.040 |
Why?
| | Drug Resistance, Bacterial | 1 | 2015 | 55 | 0.040 |
Why?
| | Phenotype | 1 | 2017 | 379 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 257 | 0.040 |
Why?
| | Treatment Failure | 1 | 2014 | 187 | 0.030 |
Why?
| | Animals | 1 | 2003 | 5312 | 0.030 |
Why?
| | Pain | 1 | 2016 | 336 | 0.030 |
Why?
| | Disease Progression | 1 | 2015 | 861 | 0.030 |
Why?
| | Patch Tests | 1 | 2011 | 2 | 0.030 |
Why?
| | Exanthema | 1 | 2011 | 15 | 0.030 |
Why?
| | Morbidity | 1 | 2011 | 71 | 0.030 |
Why?
| | Half-Life | 1 | 2009 | 19 | 0.030 |
Why?
| | Drug Dosage Calculations | 1 | 2009 | 7 | 0.030 |
Why?
| | Regression Analysis | 1 | 2011 | 319 | 0.030 |
Why?
| | Drug Evaluation | 1 | 2009 | 58 | 0.030 |
Why?
| | Kidney Failure, Chronic | 1 | 2011 | 176 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2008 | 362 | 0.020 |
Why?
| | Sulfides | 1 | 2005 | 13 | 0.020 |
Why?
| | Adrenergic beta-Agonists | 1 | 2005 | 20 | 0.020 |
Why?
| | Cyclopropanes | 1 | 2005 | 27 | 0.020 |
Why?
| | Placebos | 1 | 2005 | 89 | 0.020 |
Why?
| | Acetylcysteine | 1 | 2002 | 11 | 0.020 |
Why?
| | Free Radical Scavengers | 1 | 2002 | 13 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2002 | 155 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2002 | 79 | 0.010 |
Why?
| | Dexamethasone | 1 | 2002 | 52 | 0.010 |
Why?
| | Antiviral Agents | 1 | 2002 | 139 | 0.010 |
Why?
| | Signal Transduction | 1 | 2002 | 588 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2002 | 756 | 0.010 |
Why?
|
|
Moy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|